Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.18), $0.07 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $233.5 million versus the consensus estimate of $220.81 million.
GUIDANCE:
Sarepta Therapeutics sees FY2022 revenue of $905-920 million, versus the consensus of $899.9 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alcon (ALC) shares pop 10% on better-than-feared Q1 print
- Lightwave Logic, Inc. (LWLG) Reports Q1 Loss of $0.05
- Liquidia Corporation (LQDA) Misses Q1 EPS by 23c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!